Tag Archives: ADC Therapeutics

April, 2018

• 25 April

  ADC Therapeutics Terminates its ADCT-502 Program Targeting HER2 Expressing Solid Tumors

  

  LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that it has terminated the Phase I clinical trial to evaluate its antibody drug conjugate (ADC) ADCT-502 in patients with advanced solid …

  Share

  • Facebook
  • Twitter
  • LinkedIn

March, 2015

• 16 March

  ADC Therapeutics Submits IND for its Novel Antibody Drug Conjugate

  

  Today, Cancer drugmaker ADC Therapeutics Sarl announced that it has filed its first application to US health regulators for its lymphoma drug. The company said that it has filed an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for a Phase I clinical trial for …

  Share

  • Facebook
  • Twitter
  • LinkedIn